CD274 and adenocarcinoma: Here, in this retrospective analysis, we investigated the clinical outcomes of first-line PD-1 inhibitors plus chemotherapy in PD-L1 CPS < 5 cohort and all enrolled G/GEJ adenocarcinoma patients.